Cell Type–specific Adaptive Signaling Responses to KRASG12C Inhibition
HS Solanki, EA Welsh, B Fang, V Izumi, L Darville… - Clinical Cancer …, 2021 - AACR
Purpose: Covalent inhibitors of KRASG12C specifically target tumors driven by this form of
mutant KRAS, yet early studies show that bypass signaling drives adaptive resistance …
mutant KRAS, yet early studies show that bypass signaling drives adaptive resistance …
Cell Type-specific Adaptive Signaling Responses to KRASG12C Inhibition.
HS Solanki, EA Welsh, B Fang, V Izumi… - … Cancer Research: an …, 2021 - europepmc.org
Purpose Covalent inhibitors of KRAS G12C specifically target tumors driven by this form of
mutant KRAS, yet early studies show that bypass signaling drives adaptive resistance …
mutant KRAS, yet early studies show that bypass signaling drives adaptive resistance …
[PDF][PDF] Cell Type–specific Adaptive Signaling Responses to KRAS G12C Inhibition
HS Solanki, EA Welsh, B Fang, V Izumi, L Darville… - Clin Cancer …, 2021 - academia.edu
Purpose: Covalent inhibitors of KRASG12C specifically target tumors driven by this form of
mutant KRAS, yet early studies show that bypass signaling drives adaptive resistance …
mutant KRAS, yet early studies show that bypass signaling drives adaptive resistance …
Cell Type–specific Adaptive Signaling Responses to KRASG12C Inhibition
HS Solanki, EA Welsh, B Fang, V Izumi… - Clinical Cancer …, 2021 - cir.nii.ac.jp
抄録< jats: title> Abstract</jats: title>< jats: sec>< jats: title> Purpose:</jats: title>< jats: p>
Covalent inhibitors of KRASG12C specifically target tumors driven by this form of mutant …
Covalent inhibitors of KRASG12C specifically target tumors driven by this form of mutant …
[HTML][HTML] Cell-type Specific Adaptive Signaling Responses to KRASG12C inhibition
HS Solanki, EA Welsh, B Fang, V Izumi… - … cancer research: an …, 2021 - ncbi.nlm.nih.gov
Purpose: Covalent inhibitors of KRAS G12C specifically target tumors driven by this form of
mutant KRAS, yet early studies show that bypass signaling drives adaptive resistance. While …
mutant KRAS, yet early studies show that bypass signaling drives adaptive resistance. While …
Cell Type-specific Adaptive Signaling Responses to KRASG12C Inhibition
HS Solanki, EA Welsh, B Fang… - … : an official journal …, 2021 - pubmed.ncbi.nlm.nih.gov
Purpose Covalent inhibitors of KRAS G12C specifically target tumors driven by this form of
mutant KRAS, yet early studies show that bypass signaling drives adaptive resistance …
mutant KRAS, yet early studies show that bypass signaling drives adaptive resistance …
Cell Type-specific Adaptive Signaling Responses to KRASG12C Inhibition.
HS Solanki, EA Welsh, B Fang, V Izumi… - … Cancer Research: an …, 2021 - europepmc.org
Purpose Covalent inhibitors of KRAS G12C specifically target tumors driven by this form of
mutant KRAS, yet early studies show that bypass signaling drives adaptive resistance …
mutant KRAS, yet early studies show that bypass signaling drives adaptive resistance …